Association of the Serum Levels of the Nucleocapsid Antigen of SARS-CoV-2 With the Diagnosis, Disease Severity, and Antibody Titers in Patients With COVID-19: A Retrospective Cross-Sectional Study

Rin Yokoyama1, Makoto Kurano1,2*, Yuki Nakano1, Yoshifumi Morita1, Hiroko Ohmiya2, Yoshiro Kishi3, Jun Okada3, Chungen Qian4, Fuzhen Xia5, Fan He5, Liang Zheng5, Yi Yu5, Miyuki Mizoguchi6, Yoshimi Higurashi6, Sohei Harada6, Daisuke Jubishi6, Koh Okamoto6, Kyoji Moriya6, Tatsuhiko Kodama7 and Yutaka Yatomi1,2

1Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan, 2Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 3Sales & Marketing Division, Business Planning Department, Medical & Biological Laboratories Co., Ltd., Tokyo, Japan, 4The Key Laboratory for Biomedical Photonics of MOE at Wuhan National Laboratory for Optoelectronics-Hubei Bioinformatics & Molecular Imaging Key Laboratory, Systems Biology Theme, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology; Wuhan, China, 5Reagent R&D Center, Shenzhen YHLO Biotech Co., Ltd., Guangdong, China, 6Department of Infection Control and Prevention, The University of Tokyo, Tokyo, Japan, 7Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan

Background: Several types of laboratory tests for COVID-19 have been established to date; however, the clinical significance of the serum SARS-CoV-2 nucleocapsid (N) antigen levels remains to be fully elucidated. In the present study, we attempted to elucidate the usefulness and clinical significance of the serum N antigen levels.

Methods: We measured the serum N antigen levels in 391 serum samples collected from symptomatic patients with a confirmed diagnosis of COVID-19 and 96 serum samples collected from patients with non-COVID-19, using a fully automated chemiluminescence immunoassay analyzer.

Results: Receiver operating characteristic analysis identified the optimal cutoff value of the serum N antigen level (cutoff index, based on Youden’s index) as 0.255, which yielded a sensitivity and specificity for the diagnosis of COVID-19 of 91.0 and 81.3%, respectively. The serum N antigen levels were significantly higher in the patient groups with moderate and severe COVID-19 than with mild disease. Moreover, a significant negative correlation was observed between the serum N antigen levels and the SARS-CoV-2 IgG antibody titers, especially in patients with severe COVID-19.
INTRODUCTION

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was declared as a pandemic in early 2020, is still spreading and causing deaths and morbidity around the world in 2021 (World Health Organization, 2021). Several types of laboratory tests have been established for the diagnosis of COVID-19, including tests involving nucleic acid amplification (e.g., reverse transcription polymerase chain reaction, RT-PCR), antigen tests to detect specific components [mainly nucleocapsid antigen (N) antigen] of the SARS-CoV-2 virus, and antibody tests to detect antibodies against SARS-CoV-2. At present, RT-PCR testing is used as the gold standard for diagnosing COVID-19 (Corman et al., 2020); antigen testing has also been demonstrated to show almost similar diagnostic ability to RT-PCR testing and is used in the clinical diagnosis of SARS-CoV-2 infection (Hirotsu et al., 2020). In regard to antibody tests, they show high diagnostic sensitivity and specificity a few weeks after the onset of symptoms, while the diagnostic sensitivity is relatively low in the early phase after symptom onset (Miller et al., 2020; Nakano et al., 2021).

In addition to being useful for the diagnosis, some of these laboratory parameters have also been reported to be related to the severity of the disease. In regard to RT-PCR and antigen testing, although the number of studies is limited, it has been reported that the viral load in upper respiratory tract specimens measured using the RT-PCR test or antigen tests is associated with the severity of COVID-19 (Fajnzylber et al., 2020). In regard to antibody tests, while some studies contend that the titers of antibodies against SARS-CoV-2 do not show positive associations with the disease severity (Gozalbo-Rovira et al., 2020; Kong et al., 2020; Phipps et al., 2020), numerous other studies have demonstrated the existence of associations between SARS-CoV-2 antibody titers and the severity of COVID-19 (Röltgen et al., 2020; Bläckberg et al., 2021; De Donno et al., 2021; Fu et al., 2021; Legros et al., 2021; Lu et al., 2021; Patil et al., 2021; Shrivastava et al., 2021).

In addition to sputum, nasopharyngeal swab, nasal swab and saliva specimens, blood samples (serum and plasma) are promising for antigen testing, especially as collection of blood samples is associated with a much lower risk of contracting the infection during sampling. A few reports to date have demonstrated that the nucleocapsid antigen (N antigen) of SARS-CoV-2 can be detected in the plasma by enzyme-linked immunosorbent assay, chemiluminescence enzyme immunoassay, and a highly sensitive single molecule array immunoassay, although the clinical significance of the N antigen in blood samples of COVID-19 patients is not yet fully understood (Ogata et al., 2020; Belogiannis et al., 2021; Deng et al., 2021; Le Hingrat et al., 2021; Perna et al., 2021; Shan et al., 2021). Considering that several previous studies have demonstrated that SARS-CoV-2 RNA titers in blood samples are associated with the severity of COVID-19 (Eberhardt et al., 2020; Fajnzylber et al., 2020; Wölfel et al., 2020; Di Cristianziano et al., 2021), antigen testing in blood samples might be useful for predicting the severity of COVID-19 as well as for diagnosing the disease.

Taking into account the studies described above, in the present study, we measured the serum levels of N antigen levels using an automated chemiluminescence immunoassay (CLIA) analyzer, with the aim of investigating the usefulness and clinical significance of measurement of the serum N antigen levels in patients with COVID-19.

MATERIALS AND METHODS

Subjects

We enrolled a total of 101 patients with a confirmed diagnosis of COVID-19 who were hospitalized at The University of Tokyo Hospital from April 2020 to January 2021. COVID-19 cases were defined as follows: patients with acute respiratory infection syndrome in whom SARS-CoV-2 RNA had been detected at least once in a throat swab or sputum specimen. In addition, we also enrolled 96 patients with non-COVID-19, on the basis of the presence of respiratory symptoms, history of overseas travel, or history of close contact with a confirmed COVID-19 case, in whom there was no evidence of clinical progression and the RT-PCR test was negative. The characteristics of the enrolled subjects are described in Supplementary Table S1. We classified the patients with a confirmed diagnosis of COVID-19 into three maximum severity groups: the group with mild disease, consisting of patients who did not require oxygen supplementation, the group with moderate disease, consisting of patients who required oxygen supplementation, but not mechanical ventilatory support, and the group with severe disease, consisting of patients who required mechanical ventilatory support.

The current study was performed in accordance with the ethical guidelines established in the Declaration of Helsinki. Written informed consent for sample analysis was obtained from some of the patients. For the remaining participants, from whom written informed consent could not be obtained because they had been discharged or transferred from the

Abbreviations: ACE2, Angiotensin converting enzyme 2; AU/mL, Arbitrary units per milliliter; AUC, Area under the curve; CLIA, Chemiluminescence immunoassay; COI, Cut-off index; CI, Confidence interval; COVID-19, Coronavirus disease 2019; Ct, Cycle threshold; N antigen, Nucleocapsid antigen; NA, Neutralizing antibody; RBD, Receptor binding domain; RLU, Relative light units; RT-PCR, Reverse transcription polymerase chain reaction; ROC, Receiver operating characteristic; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2.
hospital, informed consent was obtained in the form of an opt-out on the website: patients were informed about the study on the website and those who were unwilling to be enrolled in the study were excluded.\(^1\),\(^2\) If the participants were minor, their parents or guardians could waive participating this study on behalf of them. The study design was approved by the University of Tokyo Medical Research Center Ethics Committee, which waived the need for written informed consent in cases where written informed consent could not be obtained, because only archived specimens were used and the data for this retrospective study were retrieved from the medical records (2019300NI-4 and 2020206NI).

**Samples**

We collected residual serum samples of confirmed COVID-19 and non-COVID-19 patients after routine clinical laboratory testing and kept them frozen at \(-80^\circ\)C until analysis, as previously described (Yokoyama et al., 2021). We obtained a total of 391 serum samples from the 101 patients with a confirmed diagnosis of COVID-19 (COVID-19 cases) between 1 and 16 days after symptom onset and five serum samples collected before the onset of symptoms (Supplementary Table S1). The serum samples before the onset of the infection were collected by chance since all serum samples investigated in our laboratory were stored for 3 weeks from the day when the routine laboratory testing was performed. One of the subjects of whom we collected the serum samples before the onset of COVID-19 symptoms had been hospitalized in the University of Tokyo Hospital and confirmed SARS-CoV-2 PCR negative. In other four subjects, those serum samples were collected to treat their chronic diseases and symptoms of cold were not described in medical records then. One serum sample each was used for the 96 non-COVID-19 patients (non-COVID-19 cases).

**Measurement of SARS-CoV-2 Ag and SARS-CoV-2 IgM, IgG, and Neutralizing Antibody**

Antigen testing was performed using iFlash-2019-nCoV Antigen kits and an iFlash3000 fully automated CLIA analyzer supplied by Shenzhen YHLO Biotech Co., Ltd. (Shenzhen, China). The details of the assay method are described in a previous paper (Deng et al., 2021). In brief, a sandwich complex was formed between anti-N antigen antibody-coated paramagnetic beads and acridinium ester-labeled anti-N antigen antibody, if N antigen existed in the sample. Next, under a magnetic field, nonmagnetic materials were washed out with a wash buffer. Then, the chemiluminescence reaction observed after the addition of trigger solutions was measured in relative light units (RLU). Finally, the results were determined as a cutoff index (COI) by a calibration curve generated by 2-point calibration. In accordance with the manufacturer's instructions, the cutoff value for a positive N antigen result was deemed as 1 COI in a nasal swab sample. The curves of dilution showed good linearity regardless of the presence of the SARS-CoV-2 IgM and IgG (Supplementary Figure S1 and Supplementary Table S2), suggesting that obvious interference of SARS-CoV-2 antibodies might not exist in the N antigen measurement.

The procedure for antibody testing has been described previously by some researchers (Qian et al., 2020). In brief, the IgM or IgG titers against N and spike antigen of SARS-CoV-2 in 5 μl of the sample were calculated as RLU using the analyzer and described as arbitrary units per milliliter (AU/ml) by comparing the RLU detected by the iFlash optical system with the cutoff calculated from the SARS-CoV-2 IgM or IgG calibrators containing anti-SARS-CoV-2 IgM or IgG chimeric antibody. This system was validated by us in a previous study (Yokoyama et al., 2021).

Measurement of neutralizing antibody (NAb) titer against SARS-CoV-2 was performed using iFlash-2019-nCoV NAb kit. If NAbs present in 40μl of the sample, they reacted with receptor binding domain (RBD) of spike protein of SARS-CoV-2 antigen coated on paramagnetic microparticles to form a complex. Next, the acridinium-ester-labeled angiotensin converting enzyme 2 (ACE2) conjugate was added to competitively bind to the RBD-coated particles, which have not been neutralized by the NAbs. Then, under a magnetic field, magnetic particles were adsorbed to the wall of the reaction tube and unbound materials were washed out with a wash buffer. Finally, the chemiluminescence reaction observed after the addition of trigger solutions was measured in RLU and the results were determined as AU/ml by a calibration curve generated by 4-point calibration. In accordance with the manufacturer's instruction, the cutoff value for positive neutralizing antibody result was deemed as 10 AU/ml.

**Real-Time RT-PCR for SARS-CoV-2 RNA**

The procedure for real-time RT-PCR to quantitate cycle threshold (Ct) values for SARS-CoV-2 RNA has been described previously by us (Mizoguchi et al., 2021).

**Statistical Analysis**

All statistical data were analyzed using IBM SPSS Statistics 27 (New York, United States). Mann–Whitney's U test was used for comparisons between two groups. Dunn–Bonferroni procedure was used for comparisons among more than three groups. Spearman's rank correlation coefficient was calculated to evaluate the correlations between the serum N antigen levels and Ct values in nasopharyngeal swab or serum antibody titers. A value of \(p < 0.05\) was regarded as being indicative of statistical significance in all the analyses.

**RESULTS**

**Successful Detection of SARS-CoV-2 Ag in the Serum**

First, to confirm that our measurement system could successfully detect SARS-CoV-2 antigen in serum samples, we measured

\(^{1}\)http://lab-itky.umin.jp/clinical_research/2019300NI-4.pdf

\(^{2}\)https://plaza.umin.ac.jp/utid/img/2020206NI8.pdf
the serum N antigen levels in the sera collected before and after the onset of COVID-19 symptoms in five COVID-19 cases. As shown in Figure 1A; Supplementary Figure S2, serum N antigen was below the detection limit prior to the symptom onset in all five cases. In cases 1–4, the serum N antigen level increased gradually until several days after the onset of symptoms and returned to the baseline by 10 days after symptom onset, while in case 5, the serum N antigen level remained at the baseline until it increased markedly on day 14 after symptom onset.

Second, we measured the serum N antigen levels in the 391 serum samples collected from 101 COVID-19 cases and compared them with the levels measured in one sample each collected from 96 non-COVID-19 cases (Figure 1B). The N antigen levels in the serum samples obtained from the COVID-19 cases were significantly higher than those in the samples of the non-COVID-19 cases. Moreover, the serum N antigen levels in all but one of the non-COVID-19 cases were lower than 1 COI, which was claimed as the cutoff value for nasal swab specimens by the manufacturer. In regards to the time-course of the serum N antigen levels, the levels reached the peak at 5–6 days after the onset of symptoms, decreasing gradually thereafter (Figure 1C).

Third, we investigated the correlation between the serum N antigen level and the viral load in nasopharynx and we observed that the Spearman's rank correlation coefficient was not significant (Figure 1D), suggesting that serum N antigen levels might have unique clinical characteristics, compared with the laboratory tests using the upper respiratory specimens.

ROC Analysis and Optimal Cutoff Value of Serum N Antigen Levels

Next, we performed a receiver operating characteristic (ROC) analysis using data from all the 487 samples measured (COVID-19 cases, \( n = 391 \) and non-COVID-19 cases, \( n = 96 \)), after excluding the samples collected prior to the onset of COVID-19 symptoms (Table 1). The area under the curve (AUC) for serum N antigen
was 0.932 (95% CI, 0.908–0.957). The optimal cutoff value was identified as 0.255 COI, based on Youden's index. Furthermore, we conducted ROC analysis using samples classified by the sampling day after symptom onset (Table 1). From 1 to 6 days after the onset of symptoms onset, the diagnostic specificity for COVID-19 was 99.0% when the cutoff value was set at 0.865 COI based on Youden's index.

We investigated the modulation of the diagnostic sensitivity and specificity for various cutoff values (Figure 2A). As compared to that obtained for a cutoff value of 0.2 COI, the diagnostic specificity increased to nearly 99% when the cutoff was set at 1.0 COI. At 3.2 COI, the specificity reached 100%. As shown in Figure 2A, the sensitivity decreased when the specificity improved. Next, we examined the modulation of the diagnostic sensitivity at each time-point after symptom onset when the cutoff value was set at 0.2, 0.5, 1.0, and 2.0 COI (Figures 2B–E). When the cutoff was set at 1.0 COI, the highest sensitivity (84.8%) was obtained on days 5–6 after the symptom onset.

To further validate the optimal cutoff value of serum N antigen, we calculated the overall concordance rate between the results of serum N antigen and those of RT-PCR for SARS-CoV-2 RNA in nasopharyngeal swabs, a present standard diagnostic method for COVID-19 in Japan, when the cutoff values were modified (Supplementary Table S3). The overall concordance rate was the highest at days 1–4 after the symptom onset when the cutoff value was set at 0.5 COI. At days 5–10 after the symptom onset, the optimal cutoff value was 0.255 or 1.0 COI. After 11 days, the overall concordance rates decreased.

### Association of the Serum N Antigen Levels With the Severity of COVID-19

Next, to evaluate the association between the serum N antigen levels and the maximum disease severity, we compared the serum N antigen levels among the groups with mild, moderate, and severe COVID-19, classified as described in the “Materials and Methods” section. As shown in Figure 3A, the serum N antigen levels in the groups with moderate and severe COVID-19 were significantly higher than those in the group with mild disease. We further performed sub-analyses as shown in Supplementary Figure S3. As shown in Figures 3B–D, the serum N antigen levels in the group with moderate COVID-19 were significantly higher than those in the group with mild disease on days 3–4, days 5–6, and days 15–16 after the onset of symptoms. We observed no significant differences in the serum N antigen levels between the groups with moderate and severe disease at each time-point of measurement.

To elucidate the predicting ability of the serum N antigen levels for the disease severity, we investigated the association between the representative serum N antigen levels of individual subjects at the specific time point of day 5 or day 6 (36 samples from 36 subjects) and the maximum COVID-19 severity. We observed that the serum N antigen levels in the groups with severe COVID-19 were significantly higher than those in the group with mild severity. Furthermore, as shown in Figure 3F, we performed a ROC analysis to distinguish the subjects with severe COVID-19 from those with the maximum severity of mild and moderate. The AUC for serum N antigen was 0.800 (95% CI, 0.560–1.000) and the sensitivity for severe COVID-19 was 80% and the specificity was 90.3% when the cutoff value was set at 93.5 COI, based on Youden’s index (Figure 3F). We showed the time course of serum N antigen of the cases of 13 patients, the severity of whom had progressed between days 1–16 after the symptom onset (Supplementary Figure S4). As shown in Supplementary Figure S4, in 12 of 13 patients, the peaks of serum N antigen level were observed before or on the same day as the maximum severity.

### Correlations Between the Serum N Antigen Levels and Serum Anti-SARS-CoV-2 Antibody Titers

Finally, we investigated the correlations between the serum N antigen levels and SARS-CoV-2 specific antibody titers (Table 2). When data from all the measured samples were included in the analyses, significantly negative correlations were observed between the SARS-CoV-2 IgM or IgG titers and the serum N antigen levels in the samples collected 1–16 days after the onset of symptoms (Figures 4A,B). A significant negative correlation between the serum N antigen levels and SARS-CoV-2 IgG, but not SARS-CoV-2 IgM, titers was observed between days 5 and 8 after symptom onset (Figures 4C,D). On the other hand, between days 9 and 12, significantly negative correlations were observed between the serum N antigen levels and both SARS-CoV-2 IgG and IgM titers (Figures 4E,F). Moreover, the group with severe COVID-19 showed the strongest negative correlation between the serum N antigen levels and SARS-CoV-2 IgG titers or NAb titers among the three groups with mild, moderate and severe COVID-19 (Table 2).

### DISCUSSION

Until now, the clinical usefulness of serum N antigen testing in the diagnosis of COVID-19 and the associations of the serum N antigen levels with the clinical phenotypes of COVID-19 remain to be clearly established. To the best of
our knowledge, only two reports have demonstrated the potential usefulness of measurement of the serum N antigen levels in the diagnosis of COVID-19 and the possible associations of the serum N antigen levels with the severity of COVID-19 (Deng et al., 2021; Perna et al., 2021). However, neither of these studies demonstrated the diagnostic ability or association with the disease severity of the serum N antigen levels at various time-points after the onset of COVID-19 symptoms. Since the serum N antigen levels would be expected to change dramatically on a daily basis in the acute phase of COVID-19, it would be desirable to take into account the time-point of measurement after
Yokoyama et al. Serum Nucleocapsid Antigen in COVID-19

Symptom onset to determine the diagnostic ability/association with the disease severity of the serum N antigen levels.

Although asymptomatic cases were not included in this study, measurement of serum N antigen levels might be useful for the diagnosis of symptomatic COVID-19, since N antigen was detected in the sera of not only patients with severe COVID-19 but also in patients with mild disease, who did not require oxygen supplementation (Figure 1). According to a systematic review conducted by Böger et al. (2021), the sensitivity of RT-PCR is 73.3% (95% CI 68.1–78.0%) for nasopharyngeal

---

**FIGURE 3** | Comparison of the serum N antigen levels among the three maximum severity groups. These dot plots show a comparison of the serum N antigen levels among the mild, moderate and severe group (A) overall, (B–D) at various time-points after symptom onset, and (E) using one time-point serum N antigen levels from individual patients at day 5–6. The bars show the median levels at each time-point. (F) We performed ROC analysis to discriminate the group with severe COVID-19 from other groups. *p < 0.05; **p < 0.01; ***p < 0.005.
TABLE 2 | Correlation coefficients between the serum N antigen levels and the SARS-CoV-2 IgM/IgG titers.

| Days after symptom onset | Maximum Severity | N  | v.s. SARS-CoV-2 IgM | v.s. SARS-CoV-2 IgG | v.s. SARS-CoV-2 NAb |
|-------------------------|------------------|----|---------------------|---------------------|--------------------|
|                         |                  |    | rs      | p        | rs      | p        | rs      | p        |
|                         | Mild             | 15 | −0.196  | 0.483   | −0.238  | 0.394   | −0.121  | 0.666   |
|                         | Moderate         | 8  | 0.357   | 0.385   | −0.286  | 0.493   | −0.096  | 0.823   |
|                         | Severe           |    | No sample |         |         |         |         |         |
| 1–4                     | Total mild       | 23 | −0.049  | 0.825   | −0.14   | 0.524   | −0.119  | 0.59    |
|                         | Moderate         | 31 | −0.255  | 0.166   | −0.113  | 0.547   | −0.097  | 0.605   |
|                         | Severe           | 59* | −0.283  | 0.03    | −0.492  | <0.001  | −0.399  | 0.002   |
|                         | Total mild       | 15 | −0.396  | 0.231   | −0.825  | <0.001  | −0.682  | 0.005   |
|                         | Moderate         | 59* | −0.136  | 0.165   | −0.2    | 0.04    | −0.22   | 0.25    |
|                         | Severe           | 105* | −0.169  | 0.356   | −0.211  | 0.246   | −0.345  | 0.053   |
| 5–8                     | Total mild       | 32 | −0.542  | <0.001  | −0.684  | <0.001  | −0.702  | <0.001  |
|                         | Moderate         | 80 | −0.393  | 0.2     | −0.817  | <0.001  | −0.766  | <0.001  |
|                         | Severe           | 35 | −0.372  | <0.001  | −0.544  | <0.001  | −0.516  | <0.001  |
|                         | Total mild       | 147| −0.24   | 0.249   | −0.301  | 0.143   | −0.356  | 0.081   |
|                         | Moderate         | 36 | −0.228  | 0.084   | −0.382  | 0.004   | −0.463  | <0.001  |
|                         | Severe           | 116| −0.24   | 0.02    | −0.664  | <0.001  | −0.476  | 0.003   |
| 9–12                    | Total mild       | 103| −0.365  | <0.001  | −0.288  | 0.003   | −0.317  | 0.001   |
|                         | Moderate         | 202| −0.512  | <0.001  | −0.64   | <0.001  | −0.652  | <0.001  |
|                         | Severe           | 86 | −0.275  | 0.01    | −0.748  | <0.001  | −0.742  | <0.001  |
| 13–16                   | Total mild       | 391| −0.338  | <0.001  | −0.476  | <0.001  | −0.462  | <0.001  |
| Whole period            | Mild             |    | No sample |         |         |         |         |         |
|                         | Moderate         |    | No sample |         |         |         |         |         |
|                         | Severe           |    | No sample |         |         |         |         |         |

We calculated the Spearman’s rank correlation coefficient between N antigen levels and SARS-CoV-2 IgM, IgG or NAb titers in the serum. rs, Spearman’s rank correlation coefficient. *One sample was not available to measure SARS-CoV-2 NAb titer because of short volume in the sample.

aspirate or throat swab specimens, 97.2% (95% CI 90.3–99.7%) for sputum specimens, 62.3% (95% CI 54.5–69.6%) for saliva specimens, and 7.3% (95% CI 4.1–11.7%) for blood specimens (Böger et al., 2021). In regard to antigen testing, according to one study, the sensitivity and specificity are 76.1% (range, 44.4–100%) and 100% when nasopharyngeal swab samples are used for the measurement using a CLEIA automated analyzer (Hirotsu et al., 2021). Another study showed a sensitivity and specificity of 77.8 and 99.6%, respectively, for measurement in saliva samples, using a modified cutoff value (Asai et al., 2021). In this study, the diagnostic ability for COVID-19 of serum N antigen levels measured in serum samples was deemed to be equal to or even superior to that of RT-PCR or antigen testing in other types of samples, when we used the optimal cutoff value for serum samples determined in the present study (Figure 2). The only false-positive test result in a non-COVID-19 case was due to the presence of an autoimmune disease, considering that the patient had allergic granulomatous angiitis. In the validation of the cutoff value, the overall concordance rate between RT-PCR tests in nasopharyngeal swab and serum N antigen tests shows that the most optimal cutoff value in days 1–4 after the COVID-19 symptom onset might be 0.5 COI, the optimal cutoff value in days 5–10 was 0.255 or 1.0 COI, and after day 11, the overall concordance rates decreased (Supplementary Table S3). These results suggested that the cutoff value for the diagnosis of COVID-19 should be determined, according to the days after the symptom onset.

In regard to the ability of the serum N antigen levels to predict the maximum disease severity of COVID-19, as shown in Figures 3A–E, the subjects with moderate and severe COVID-19 tended to show higher serum N antigen levels than the subjects with mild disease. As shown in Supplementary Figure S4, the increase of serum N antigen levels was prior to the progression of disease. These results were consistent with previous reports suggesting a possible association between the maximum disease severity and viral RNA levels in the blood (Eberhardt et al., 2020; Fajnzylber et al., 2020). The difference in the serum N antigen levels between patients with mild and severe disease may become apparent at an earlier time than the difference in the anti-SARS-CoV-2-specific antibody titers, which begin to increase almost 1 week after the onset of symptoms (Jin et al., 2020; Long et al., 2020). It is noteworthy that no difference in the serum N antigen level was observed between the patients with moderate and severe disease. Although further studies are necessary, these results suggest the possibility that the viral load might determine the disease severity in patients with more than moderately severe disease, and that factors other than the viral load, such as complications and the immunological state of the subjects might contribute to the determination of the disease severity in cases with severe COVID-19. In any case, the serum N antigen level may serve as an early biomarker for predicting the maximum disease grade of severe COVID-19; for example, when the serum N antigen levels were over 93.5% at days 5–6, the clinicians need to consider the further progression of the disease severity and may need to transfer the subjects to the hospital which can offer intensive care with mechanical respiratory ventilation.

Measurement of the serum N antigen levels is also expected to allow a better understanding of the pathogenesis of COVID-19, in addition to its possible clinical usefulness of this laboratory.
test. For example, we observed a negative correlation between the serum N antigen levels and SARS-CoV-2 antibody titers (Table 2 and Figure 4). Considering that the titer of antibodies might be higher in subjects with a higher viral load, the present inverse correlation between the serum N antigen levels and antibody titers might possibly be a result of the antigen levels remaining at high levels in subjects with lower antibody titers, which might be insufficient for rapid clearance of the virus. Actually, this inverse correlation may be consistent with a previous study demonstrating that the production of antibody containing neutralizing antibody is delayed in patients with severe disease (Lucas et al., 2021).

This study had several limitations. First, since the study was a retrospective cross-sectional study, a prospective
longitudinal study is necessary in the future to confirm the results of the study. Second, to validate the usefulness of serum N antigen measurement in the diagnosis and severity prediction of COVID-19, a study comparing the serum N antigen levels with the viral load determined by RT-PCR or the N antigen level in respiratory tract specimens collected at the same time as the blood specimens would be desirable. Finally, in the present study, we measured the serum N antigen levels only in symptomatic subjects who were hospitalized and could not elucidate the usefulness of serum antigen level measurement in asymptomatic cases or in the general population. Nonetheless, we believe that the present study might help us to understand the potential usefulness of serum N antigen measurement in the management of COVID-19.

In conclusion, we demonstrated the usefulness of measuring the serum levels of the SARS-CoV-2 N antigen using a fully automated analyzer. Serum N antigen measurement showed a high sensitivity and specificity for the diagnosis of COVID-19 and might serve as an early predictive marker of the maximum disease severity of COVID-19. Serum N antigen measurement may also contribute to a better understanding of the pathogenesis of COVID-19, such as by showing the negative correlation between serum N antigen levels and SARS-CoV-2 antibody titers, revealed for the first time in the present study.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by the University of Tokyo Medical Research Center Ethics Committee. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS
RY participated in the experiments and data analysis and drafted the initial manuscript. MK participated in the study design and helped in drafting the manuscript. YN and YM participated in the experiments. HO participated in the data analysis and visualization. CQ, FX, FH, LZ, YYu, YK, and JO developed the antibody measurement system. MM, YH, and SH participated in the data analysis and the discussion and helped in drafting the manuscript. DJ, KO, KM, and TK participated in the discussion and helped in drafting the manuscript. YYa conceived the study, coordinated the study design, and helped in drafting the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING
This work was supported by the Research Grants in the Natural Sciences from the Mitsubishi Foundation.

ACKNOWLEDGMENTS
We are thankful to the Murakami Foundation for the donation of the iFlash3000 to The University of Tokyo Hospital.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2021.791489/full#supplementary-material

REFERENCES
Asai, N., Sakanashi, D., Ohashi, W., Nakamura, A., Kawamoto, Y., Miyazaki, N., et al. (2021). Efficacy and validity of automated quantitative chemiluminescent enzyme immunoassay for SARS-CoV-2 antigen test from saliva specimen in the diagnosis of COVID-19. J. Infect. Chemother. 27, 1039–1042. doi: 10.1016/J.JIAC.2021.03.021
Belogiannis, K., Florou, V. A., Fragkou, P. C., Ferous, S., Chatzis, L., Polyzou, A., et al. (2021). SARS-CoV-2 antigenemia as a confounding factor in immunodiagnostic assays: A case study. Viruses 13:1143. doi: 10.3390/v13061143
Blackberg, A., Fernström, N., Sarbrant, E., Rasmussen, M., and Sunnerhagen, T. (2021). Antibody kinetics and clinical course of COVID-19 a prospective observational study. PLoS One 16:e0248918. doi: 10.1371/JOURNAL.PONE.0248918
Röger, B., Fachi, M. M., Vilhenia, R. O., Cobre, A. F., Tonin, F. S., and Pontarolo, R. (2021). Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19. Am. J. Infect. Control 49, 21–29. doi: 10.1016/j.ajic.2020.07.011
Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K. W., et al. (2020). Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eur. Surc. 25:2000045. doi: 10.2807/1560-7917.ES.2020.25.3.2000045

De Donno, A., Lobreglio, G., Panico, A., Grassi, T., Bagordo, E., Bozzetti, M. P., et al. (2021). Igm and igg profiles reveal peculiar features of humoral immunity response to sars-cov-2 infection. Int. J. Environ. Res. Public Health 18, 1–16. doi: 10.3390/ijerph18031318
Deng, Q., Ye, G., Pan, Y., Xie, W., Yang, G., Li, Z., et al. (2021). High performance of SARS-CoV-2 protein antigen chemiluminescence immunoassay as frontline testing for acute phase COVID-19 diagnosis: a retrospective cohort study. Front. Med. 6:76560. doi: 10.3389/FMED.2021.676560
Di Cristanziano, V., Meyer-Schwickerath, C., Eberhardt, K. A., Rybniker, J., Heger, E., Knops, E., et al. (2021). Detection of SARS-CoV-2 viremia before onset of COVID-19 symptoms in an allo-transplanted patient with acute leukemia. Bone Marrow Transplant. 56, 716–719. doi: 10.1038/s41409-020-01059-y
Eberhardt, K. A., Meyer-Schwickerath, C., Heger, E., Knops, E., Lehmann, C., Rybniker, J., et al. (2020). RNAemia corresponds to disease severity and antibody response in hospitalized COVID-19 patients. Viruses 12:1045. doi: 10.3390/v12091045
Fajnzylber, J., Regan, J., Coxen, K., Corry, H., Wong, C., Rosenthal, A., et al. (2020). SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat. Commun. 11, 5493–5499. doi: 10.1038/s41467-020-19057-5
Fu, Y., Li, Y., Guo, E., He, L., Liu, J., Yang, B., et al. (2021). Dynamics and correlation among viral positivity, seroconversion, and disease severity in...
COVID-19: a retrospective study. Ann. Intern. Med. 174, 453–461. doi: 10.7326/M20-3337

Gonzalo-Rovira, R., Gimenez, E., Latorre, V., Francés-Gómez, C., Albert, E., Buesa, J., et al. (2020). SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients. J. Clin. Virol. 131:104611. doi:10.1016/j.jcvi.2020.104611

Hirotsu, Y., Maejima, M., Shibusawa, M., Amemiya, K., Nagakubo, Y., Hosaka, K., et al. (2021). Prospective study of 1308 nasopharyngeal swabs from 1035 patients using the LUMIPULSE SARS-CoV-2 antigen test: comparison with RT-qPCR. Int. J. Infect. Dis. 105, 7–14. doi:10.1016/j.ijid.2020.08.029

Jin, Y., Wang, M., Zuo, Z., Fan, C., Ye, F., Cai, Z., et al. (2020). Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019. Int. J. Infect. Dis. 94, 49–52. doi:10.1016/j.ijid.2020.03.065

Kong, W. H., Zhao, R., Zhou, J. B., Wang, F., Kong, D. G., Sun, J. B., et al. (2020). Serologic response to SARS-CoV-2 in COVID-19 patients with different severity. Virol. Sin. 35, 752–757. doi:10.1093/virol/ssi107

Le Hingrat, Q., Visseaux, B., Laouenan, C., Tubiana, S., Bouadma, L., Yazdanpanah, Y., et al. (2021). Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives. Clin. Microbiol. Infect. 27, 789.e1–789.e5. doi:10.1016/j.cmi.2020.11.025

Legros, V., Denolly, S., Vogrig, M., Boson, B., Siret, E., Rigail, J., et al. (2021). A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell. Mol. Immunol. 18, 318–327. doi:10.1038/s41423-020-00588-2

Long, Q. C., Liu, B. Z., Deng, H. J., Wu, G. C., Deng, K., Chen, Y. K., et al. (2020). Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845–848. doi:10.1038/s41591-020-0987-1

Lu, W., Wu, P., He, L., Meng, Y., Wu, P., Ding, W., et al. (2021). Dynamic antibody responses in patients with different severity of COVID-19: A retrospective study. Infect. Dis. Ther. 10, 1379–1390. doi:10.1007/s40121-021-00423-9

Lucas, C., Klein, J., Sundaram, M. E., Liu, F., Wong, P., Silva, J., et al. (2021). Delayed production of neutralizing antibodies correlates with fatal COVID-19. Nat. Med. 27, 1178–1186. doi:10.1038/s41591-021-01355-0

Miller, T. E., Beltran, W. F. G., Bard, A. Z., Gogakos, T., Anahitar, M. N., Astudillo, M. G., et al. (2020). Clinical sensitivity and interpretation of PCR and serological COVID-19 diagnostics for patients presenting to the hospital. FASEB J. 34, 13877–13884. doi:10.1096/fj.202001700RR

Mizoguchi, M., Harada, S., Okamoto, K., Higurashi, Y., Ikeda, M., and Moriya, K. (2021). Comparative performance and cycle threshold values of 10 nucleic acid amplification tests for SARS-CoV-2 on clinical samples. PLoS One 16:e0252757. doi:10.1371/journal.pone.0252757

Nakano, Y., Kurano, M., Morita, Y., Shimura, T., Yokoyama, R., Qian, C., et al. (2021). Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan. Sci. Rep. 11:2776. doi:10.1038/s41598-021-82428-5

Ogata, A. F., Maley, A. M., Wu, C., Gilboa, T., Norman, M., Lazarovits, R., et al. (2020). Ultra-sensitive serial profiling of SARS-CoV-2 antigens and antibodies in plasma to understand disease progression in COVID-19 patients with severe disease. Clin. Chem. 66, 1562–1572. doi:10.1093/CLINCHEM/HVAA213

Patil, H. P., Rane, P. S., Shrivastava, S., Palkar, S., Lalwani, S., Mishra, A. C., et al. (2021). Antibody (IgA, IgG, and IgG subtype) responses to SARS-CoV-2 in severe and nonsevere COVID-19 patients. Viral Immunol. 34, 201–209. doi:10.1089/vim.2020.0321

Perna, F., Bruzzaniti, S., Piemonte, E., Maddaloni, V., Attripaldi, L., Sale, S., et al. (2021). Serum levels of SARS-CoV-2 nucleocapsid antigen associate with inflammatory status and disease severity in COVID-19 patients. Clin. Immunol. 226:108720. doi:10.1016/j.clim.2021.108720

Phippes, W. S., SoRelle, J. A., Li, Q. Z., Mahmimainathan, L., Arau, E., Markantonis, J., et al. (2020). SARS-CoV-2 antibody responses do not predict COVID-19 disease severity. Am. J. Clin. Pathol. 154, 459–465. doi:10.1093/ajcp/AQAA123

Qian, C., Zhou, M., Cheng, F., Lin, X., Gong, Y., Xie, X., et al. (2020). Development and multicenter performance evaluation of fully automated SARS-CoV-2 IgM and IgG immunoassays. Clin. Chem. Lab. Med. 58, 1601–1607. doi:10.1515/cclm-2020-0548

Röllgen, K., Powell, A. E., Wirz, O. F., Stevens, R. A., Hogan, C. A., Najeeb, J., et al. (2020). Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci. Immunol. 5:240. doi:10.1126/sciimmunol.abe0240

Shan, D., Johnson, J. M., Fernandes, S. C., Subh, H., Hwang, S., Wuelfing, D., et al. (2021). N-protein presents early in blood, dried blood and saliva during asymptomatic and symptomatic SARS-CoV-2 infection. Nat. Commun. 12:1931. doi:10.1038/s41467-021-22072-9

Shrivastava, S., Palkar, S., Shah, J., Rane, P., Lalwani, S., Mishra, A. C., et al. (2021). Early and high SARS-CoV-2 neutralizing antibodies are associated with severity in COVID-19 patients from India. Am. J. Trop. Med. Hyg. 1, 401–406. doi:10.4269/ajtmh.21-0014

Wölfel, R., Cormier, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., et al. (2020). Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465–469. doi:10.1038/s41586-020-2196-x

World Health Organization. (2021). World Health Organization Coronavirus Disease (COVID-19): Weekly Epidemiological Update. Available at: https://reliefweb.int/report/world/coronavirus-disease-covid-19-weekly-epidemiological-update-3-august-2021 (Accessed August 4, 2021).

Yokoyama, R., Kurano, M., Morita, Y., Shimura, T., Nakano, Y., Qian, C., et al. (2021). Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan. PLoS One 16. doi:10.1371/journal.pone.0247711

Conflict of Interest: The present study was a collaborative research project among the University of Tokyo, Shenzhen YHLO Biotech Co., Ltd., and Medical & Biological Laboratories Co., Ltd. FX, FH, LZ, and YU are the employees of Shenzhen YHLO Biotech Co., Ltd., and YK, JO, and HO are the employees of Medical & Biological Laboratories Co., Ltd.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Yokoyama, Kurano, Nakano, Morita, Ohmiya, Kishi, Okada, Qian, Xia, He, Zheng, Yu, Mizoguchi, Higurashi, Harada, Jubihi, Okamoto, Moriya, Kodama and Yatomi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.